



**Ref: Syn/CS/SE/Reg 30/2021-22/Jun/25**

**Syngene International Limited**  
Biocon SEZ, Biocon Park, Plot No. 2 & 3,  
Bommasandra Industrial Area, IV Phase,  
Jigani Link Road, Bengaluru 560099,  
Karnataka, India.  
T +91 80 6891 8000  
F +91 80 6891 8808  
CIN: L85110KA1993PLC014937  
[www.syngeneintl.com](http://www.syngeneintl.com)

June 22, 2021

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
<b>Scrip Code: 539268</b>	<b>Scrip Symbol: SYNGENE</b>

**Sub: Intimation of Appointment of Additional Director (Independent, Non-Executive).**

**Reference: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015.**

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we wish to inform you that, the Board of Directors of the Company ("Board"), vide resolution passed on Tuesday, June 22, 2021, has considered and approved the appointment of Dr. Kush Parmar (DIN: 09212020) as an Additional Director (Independent, Non-Executive), for a tenure commencing from today (i.e. the date of allotment of DIN) till the conclusion of the 31<sup>st</sup> Annual General Meeting of the Company proposed to be held in 2024.

Dr. Kush Parmar (DIN: 09212020) is not debarred from holding the office of a Director by virtue of any SEBI order or any other authority.

Additional details as required under SEBI LODR Regulations and SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015, with regard to the appointment of Dr. Kush Parmar (DIN: 09212020), is enclosed as **Annexure A**.

The above-mentioned information will also be available on website of the Company [www.syngeneintl.com](http://www.syngeneintl.com).

Kindly take the intimation on record and acknowledge receipt of the same.

Yours faithfully,

**For SYNGENE INTERNATIONAL LIMITED**

\_\_\_\_\_  
**Priyadarshini Mahapatra**  
**Company Secretary and Compliance Officer**

**Annexure A.**

**Appointment of Dr. Kush Parmar (DIN: 09212020) as an Additional Director (Independent, Non-Executive), of the Company, with effect from June 22, 2021.**

Sl. No.	Details required	Particulars
1	Reason for change	Appointment
2	Date and term of appointment	<p>Appointment date: June 22, 2021.</p> <p>The term of appointment is till the conclusion of the 31<sup>st</sup> Annual General Meeting of the Company proposed to be held in 2024.</p>
3	Brief profile	<p><b><u>Brief Profile:</u></b></p> <p>Dr. Kush Parmar, M.D., Ph.D. is a Managing Partner at 5AM Ventures, a life sciences venture capital firm with offices in Boston and San Francisco, with over \$2B USD under management. Dr. Parmar serves as Chairman or Director on the Boards of Akouos (NASDAQ: AKUS), Entrada, Homology (NASDAQ: FIXX), Rallybio and Vor Biopharma (NASDAQ: VOR). He previously served as Board Member or Observer for Achaogen (NASDAQ: AKAO), Arvinas (NASDAQ: ARVN), Audentes (NASDAQ: BOLD; acquired by Astellas), Envoy (acquired by Takeda) and scPharmaceuticals (NASDAQ: SCPH) and as Acting VP of Strategy and Corporate Development at Novira (acquired by J&amp;J). Dr. Parmar serves on the Advisory Boards of Harvard Medical School, Penn Medicine, Princeton University's Department of Molecular Biology, and the Grace Science Foundation. He is a founding member of the COVID R&amp;D Alliance along with several heads of R&amp;D of global pharmaceutical companies. Prior to his career in biotech, Dr. Parmar was at Harvard Medical School, where he was an NIH-sponsored M.D./Ph.D. Physician Scientist Fellow in the Harvard-MIT Health Sciences and Technology Program. He completed clinical clerkships at the Massachusetts General &amp; Brigham and Women's Hospitals. At Princeton University, Dr. Parmar worked on developmental genetics with Eric F. Wieschaus (Nobel Prize in Medicine in 1995). He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University and an M.D. from Harvard Medical School. Dr. Parmar is based in the Boston, MA office.</p>
4	Disclosure of relationships between Directors	Dr. Kush Parmar is not related to any of the Directors of the Company.